Lon­za bags Cap­sug­el and its oral drug de­liv­ery tech for $5.5B: Biotech vet Truex named COO at Syn­log­ic

Switzer­land’s Lon­za has bagged Mor­ris­town, NJ-based Cap­sug­el for $5.5 bil­lion in a deal de­signed to make the phar­ma in­dus­try sup­pli­er a world leader in drug de­liv­ery tech and man­u­fac­tur­ing. The buy­out gives the Swiss buy­er a big role to play in the oral drug and con­sumer mar­kets. It al­so reg­is­tered as a big pre­mi­um for the own­er, KKR, the lat­est ex­am­ple that de­sir­able as­sets in bio­phar­ma are at­tract­ing big bids — which isn’t al­ways wel­come by in­vestors. Lon­za ex­pects to carve about $30 mil­lion in cost “syn­er­gies” as well as $15 mil­lion in an­nu­al tax sav­ings out of the buy­out. Cap­sug­el has 3,600 staffers work­ing in 13 fa­cil­i­ties scat­tered around the globe.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER